A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine

医学 偏头痛 耐受性 加药 自然科学 不利影响 苏马曲普坦 降钙素基因相关肽 内科学 儿科 麻醉 化疗 兴奋剂 贝伐单抗 血管抑制剂 受体 神经肽
作者
Robert S. Croop,Gary Berman,David Kudrow,Kathleen Mullin,Alexandra Thiry,Meghan Lovegren,Gilbert J L'Italien,Richard B. Lipton
出处
期刊:Cephalalgia [SAGE Publishing]
卷期号:44 (4): 3331024241232944-3331024241232944 被引量:60
标识
DOI:10.1177/03331024241232944
摘要

Background The present study evaluated the long-term safety and tolerability of rimegepant, an orally administered small molecule calcitonin gene-related peptide receptor antagonist, in people with migraine. Methods This multicenter, long-term, open-label safety study included adults (≥18 years) with ≥1 year history of migraine who were sequentially enrolled into three groups: participants in the first two groups had either 2–8 or 9–14 moderate to severe migraine attacks per month by history and treated as needed ( pro re nata [PRN]) with one rimegepant 75 mg oral tablet up to once per calendar day for 52 weeks (PRN 2–8 and PRN 9–14); a third group, included to collect safety data during higher-frequency dosing, had 4–14 moderate to severe migraine attacks per month by history and who took one rimegepant tablet every other day as scheduled dosing plus PRN dosing of one rimegepant tablet for migraine attacks of any severity on nonscheduled dosing days for 12 weeks (every other day (EOD) + PRN). Results Overall, 1800 participants self-administered rimegepant (PRN 2–8: n = 1033; PRN 9–14: n = 481; EOD + PRN: n = 286). The most common on-treatment adverse events (AEs) were upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. Serious AEs considered possibly (n = 1) or unlikely (n = 9) related to rimegepant were reported in ten (0.6%) participants. No signal of drug-induced liver injury because of rimegepant was identified. Conclusions Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks or PRN for up to 52 weeks was safe and well tolerated. No signal of hepatotoxicity, potential drug abuse, or medication-overuse headache was identified. Trial registration: Clinicaltrials.gov: NCT03266588.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
简爱完成签到 ,获得积分10
1秒前
LEO2025完成签到 ,获得积分10
2秒前
tszjw168发布了新的文献求助10
2秒前
大方的仙人掌完成签到,获得积分10
2秒前
L050完成签到 ,获得积分10
5秒前
Charlie完成签到 ,获得积分10
5秒前
幸福妙柏完成签到 ,获得积分10
6秒前
宁静的夏天的应助被学不可以已采纳,获得500
9秒前
Chaowei_L完成签到,获得积分10
10秒前
海布里的风完成签到 ,获得积分10
13秒前
王大发完成签到,获得积分10
13秒前
沉默的元枫完成签到,获得积分10
16秒前
tt完成签到,获得积分10
16秒前
乐观的自行车完成签到 ,获得积分10
17秒前
Hansky完成签到,获得积分10
18秒前
乖咪甜球球完成签到 ,获得积分10
21秒前
季末默相依完成签到,获得积分10
22秒前
24秒前
yiyi完成签到 ,获得积分10
24秒前
活力的鹰完成签到 ,获得积分10
24秒前
sea完成签到 ,获得积分10
26秒前
wzk完成签到,获得积分10
28秒前
linpeng发布了新的文献求助10
29秒前
LaixS完成签到,获得积分0
30秒前
要笑cc完成签到,获得积分0
32秒前
顺心妙之完成签到 ,获得积分10
32秒前
dktrrrr完成签到,获得积分10
33秒前
宣宣宣0733完成签到,获得积分0
34秒前
胡质斌完成签到,获得积分0
36秒前
维C完成签到 ,获得积分10
37秒前
大明发布了新的文献求助10
39秒前
CX完成签到,获得积分10
40秒前
40秒前
华仔的应助被科研通管家采纳,获得10
41秒前
NexusExplorer的应助被科研通管家采纳,获得10
41秒前
41秒前
不安碧灵完成签到,获得积分10
44秒前
linpeng完成签到,获得积分10
44秒前
宋艳芳完成签到,获得积分10
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012